Vitamin C Human Clinical Research: What the Evidence Shows

Vitamin C is one of the most widely used supplements in the world, and one of the most argued about. Does it prevent colds, protect the heart, lower blood pressure or help fight cancer? Headlines say yes, no and maybe, often on the same day. This page cuts through the noise by reviewing what human clinical trials and systematic reviews actually found, how strong each finding is, and where the evidence is thin. If you want a source-based answer rather than a sales pitch, read on. We start with the short version, then show the data behind it.

Executive Evidence Summary: Vitamin C at a Glance

Across decades of human research, a consistent pattern emerges. Ascorbic acid is clearly essential, and deficiency causes scurvy. Beyond preventing deficiency, the benefits seen in trials are usually modest, specific to certain groups, or absent.

• Common cold: regular supplementation does not reduce how many colds people catch in the general population, but it modestly shortens their duration. Benefit for prevention appears in people under extreme physical stress.
• Blood pressure: a meta-analysis of short trials found small average reductions, although the long-term meaning is unclear.
• Heart disease and cancer prevention: large, long randomized trials of 500 mg per day found no reduction in cardiovascular events or total cancer.
• Critical illness and sepsis: early excitement was not confirmed. The largest trial to date found no benefit and a signal of possible harm.
• Eye health: a combination supplement that included it slowed progression of advanced macular degeneration in one large trial, but the effect cannot be attributed to the vitamin alone.
• Safety: doses up to the 2,000 mg upper limit are generally well tolerated, with gastrointestinal upset and kidney stone risk the main concerns at higher intakes.

The bottom line is that food-based intake and correcting low status matter most, while high-dose supplements have not been shown to deliver the broad benefits often claimed.

Research Question and Scope

The question this page addresses is simple: in human beings, what do controlled studies show about the effects of ascorbic acid supplementation on health outcomes, and how reliable is that evidence?

We focus on human data. Cell and animal studies are mentioned only where needed to explain why a trial was run. We emphasize outcomes that matter to patients, such as illness, events and survival, over laboratory markers. We also consider safety, because a benefit means little without a clear picture of risk. This is an educational review and not personal medical advice.

Search and Inclusion Methodology

This article is a narrative evidence review, not a new formal systematic review. We built it by working down a hierarchy of evidence, following the spirit of PRISMA reporting principles and the GRADE approach to rating certainty.

1. Cochrane reviews and meta-analyses of randomized controlled trials (RCTs) were given the greatest weight, because they combine many trials and use predefined methods.
2. Large, landmark RCTs were included when they tested clinically meaningful endpoints, such as cardiovascular events or mortality.
3. Observational studies were considered mainly for safety signals, such as kidney stones, and are labeled as such because they cannot prove cause and effect.
4. Excluded or downweighted: animal and cell studies, small uncontrolled studies, case reports, and trials that tested only combination products without a way to isolate the vitamin.

Each study is described with its design, population, dose, duration and funding where known. Readers should check the references for full details, and recheck for newer trials before relying on any single finding.

Vitamin C Clinical Trials by Health Outcome

The common cold

This is the best-studied question. A Cochrane review by Hemila and Chalker pooled dozens of trials. In 29 comparisons involving more than 11,000 participants who took at least 0.2 g daily as regular prevention, the risk of catching a cold was not meaningfully reduced in the general population. However, colds were somewhat shorter, by about 8 percent in adults and 14 percent in children.

A notable exception emerged in a small group of trials in people under heavy short-term physical stress, such as marathon runners, skiers and soldiers training in subarctic conditions. In these groups, regular supplementation roughly halved the risk of getting a cold. These trials were few and small, so the finding is interesting rather than conclusive.

Starting supplements only after symptoms appear did not consistently shorten or ease colds in the trials reviewed.

Blood pressure

A meta-analysis of 29 RCTs, with about 1,400 adults, found that supplementation was associated with a small drop in blood pressure: roughly 3.8 mmHg for systolic and 1.5 mmHg for diastolic pressure. The typical dose was around 500 mg per day for about 8 weeks. The authors noted that the trials were short and varied, and that larger, longer studies in people with high blood pressure were needed.

Cardiovascular events

The Physicians' Health Study II followed 14,641 male physicians for about 8 years. Those assigned to 500 mg of ascorbic acid daily had no lower risk of major cardiovascular events than those on placebo. The Women's Antioxidant Cardiovascular Study, with more than 8,000 women at higher cardiovascular risk and a similar dose, also found no effect over roughly nine years. A Cochrane review of supplementation for primary prevention concluded there was no evidence that it reduces cardiovascular disease events.

Cancer

In the Physicians' Health Study II, 500 mg per day did not reduce total cancer incidence or prostate cancer. For treatment, a randomized, double-blind trial from the Mayo Clinic gave 10 g daily by mouth to people with advanced cancer and found no improvement in survival or symptoms over placebo.

Intravenous (IV) administration produces much higher blood levels than oral intake, and researchers have continued to study it. A small early-phase study in ovarian cancer reported that IV ascorbate given alongside chemotherapy was feasible and may have reduced some chemotherapy side effects. Early-phase studies cannot show whether it improves survival, and larger controlled trials are needed.

Sepsis and critical illness

Small studies suggested that IV ascorbic acid, sometimes with hydrocortisone and thiamine, might improve outcomes in sepsis. Larger trials have not confirmed this. In CITRIS-ALI (167 patients with sepsis and severe respiratory failure), IV infusion did not improve the primary organ-failure score. A lower 28-day mortality was seen in an exploratory analysis, which cannot be treated as proof. The VITAMINS trial found no improvement in time alive and free of vasopressors with the combination therapy.

The largest trial, LOVIT, enrolled 872 adults with sepsis in intensive care. The composite of death or persistent organ dysfunction at 28 days occurred more often with IV ascorbic acid (about 44 percent) than with placebo (about 38 percent). This is a strong reason why IV use outside a medical setting is not supported.

Age-related macular degeneration

In the AREDS trial, 3,640 participants received a combination of 500 mg ascorbic acid, vitamin E, beta-carotene, zinc and copper, or placebo, for about six years. The combination reduced progression to advanced macular degeneration in people at high risk. Because several ingredients were given together, the effect cannot be assigned to one nutrient.

Uric acid and gout

A meta-analysis of RCTs found that oral supplementation modestly lowered serum uric acid. Whether this prevents gout attacks has not been established by clinical-outcome trials, so the finding is a lab marker result.

Exercise adaptation

A randomized trial in healthy young men found that high-dose ascorbic acid with vitamin E blunted some cellular adaptations to endurance training. Effects on actual performance were not the main focus, but the study suggests that more is not always better for active people.

Mortality

A Cochrane review of antioxidant supplements found no convincing evidence that ascorbic acid reduces mortality in healthy people or those with disease, and raised concerns about some other antioxidants such as beta-carotene and vitamin E.

Summary Table of Key Human Studies

Study	Design	Participants	Dose and duration	Main finding
Hemila and Chalker, 2013	Cochrane review of RCTs	Over 11,000 in prevention comparisons	0.2 g or more daily, varied	Colds shorter by about 8 percent (adults) and 14 percent (children); incidence not reduced overall
Juraschek et al., 2012	Meta-analysis of 29 RCTs	About 1,400 adults	Median 500 mg/day, median 8 weeks	Systolic about 3.8 mmHg and diastolic about 1.5 mmHg lower
Physicians' Health Study II (Sesso, 2008)	RCT	14,641 male physicians	500 mg/day, about 8 years	No reduction in major cardiovascular events
Physicians' Health Study II (Gaziano, 2009)	RCT	Same cohort	500 mg/day, about 8 years	No reduction in total cancer
Women's Antioxidant Cardiovascular Study (Cook, 2007)	RCT	Over 8,000 women at higher risk	500 mg/day, about 9 years	No effect on cardiovascular events
Moertel et al., 1985	RCT	100 people with advanced cancer	10 g/day orally	No survival benefit
CITRIS-ALI (Fowler, 2019)	RCT	167 with sepsis and severe respiratory failure	IV, 96 hours	No difference in primary organ-failure outcome
LOVIT (Lamontagne, 2022)	RCT	872 with sepsis in intensive care	IV, up to 96 hours	More death or persistent organ dysfunction vs placebo
AREDS (2001)	RCT	3,640 people at risk of macular degeneration	500 mg in combination, about 6 years	Less progression to advanced disease for the combination

Study Design Quality

The quality of the evidence differs by outcome. The strongest findings come from double-blind, placebo-controlled RCTs with large samples and clear endpoints, such as the Physicians' Health Study II and LOVIT. These designs reduce bias and allow cause-and-effect conclusions.

Other areas rest on weaker designs. The blood pressure meta-analysis combined many small, short trials with varied methods. Studies on uric acid measure a lab marker, not illness. Early IV cancer studies are small and not designed to show survival benefit. Observational studies, for example those linking supplements with kidney stones in men, can reveal safety signals but cannot rule out other explanations.

Common design concerns include inadequate blinding when participants can tell what they are taking, incomplete follow-up, short duration and reporting of many outcomes with only some highlighted. When reading any new trial, check whether the primary outcome was declared in advance.

Participant Characteristics

Who was studied matters as much as what was tested. Many large prevention trials enrolled well-nourished adults in high-income countries, such as US physicians, who probably started with adequate vitamin status. In such people, extra intake may add little because the body regulates blood levels and excretes the excess.

By contrast, the signals of benefit in colds came from groups under extreme physical stress, where demands may be higher. Trials in critical illness enrolled very sick patients who often have low levels at baseline and who respond differently to IV dosing. Smokers have higher requirements, and the recommended intake is raised by 35 mg per day for them.

Other gaps limit generalization: few trials focused on older adults, pregnant women, children outside cold studies or people with low baseline status. Results from one population should not be assumed to apply to another.

Dose and Form Used

Doses in human studies range widely. Prevention trials commonly used 200 mg to 1,000 mg per day by mouth. Cancer and critical-care trials used much higher amounts, from 10 g orally to roughly 50 mg per kilogram of body weight given intravenously every six hours.

For context, the US Recommended Dietary Allowance is 90 mg per day for adult men and 75 mg for adult women, and the tolerable upper intake level is 2,000 mg per day. Pharmacokinetic work shows that blood levels level off at intakes around 200 to 400 mg daily, and that the percentage absorbed falls as single doses rise above about 1 g. Oral and IV routes are therefore not comparable: IV bypasses the gut and can produce much higher blood concentrations.

Supplements come as ascorbic acid, sodium or calcium ascorbate, products with bioflavonoids and liposomal formulations. Small studies suggest differences in absorption between common forms are modest, and no large outcome trials compare them. Claims that one form is far superior are not currently backed by strong human evidence.

Duration, Primary Endpoints and Results

Trial length and the choice of endpoint strongly shape what a study can show.

Duration. Blood pressure and uric acid trials typically lasted weeks to a few months, long enough to see marker changes but not long enough to show effects on illness. Cold prevention trials ran for the length of a cold season. Cardiovascular and cancer prevention trials ran 8 to 10 years, which is appropriate for diseases that develop slowly. Sepsis trials were short by design, with treatment over four days and follow-up at 28 days.

Primary endpoints. Strong trials declare one primary endpoint in advance. Examples include major cardiovascular events (Physicians' Health Study II), a composite of death or persistent organ dysfunction (LOVIT) and progression to advanced macular degeneration (AREDS). Others relied on surrogate endpoints, meaning measurements such as blood pressure or serum urate that are linked to disease but are not the disease itself.

Results. Taken together, trials with hard clinical endpoints were largely neutral for prevention at 500 mg per day. Positive findings clustered in the surrogate outcomes, in cold duration and in a multi-ingredient eye supplement. In critical illness, the biggest trial pointed in the wrong direction.

Clinical Significance

Statistical significance is not the same as clinical significance. A result can be real and still be too small to matter to an individual.

• Cold duration: an 8 percent reduction in adults corresponds to a fraction of a day for a typical week-long cold. Some people may value that, but it is not a dramatic effect.
• Blood pressure: a drop of about 4 mmHg systolic is similar in size to a small lifestyle change. It could matter at the population level, but the trials were short, and no trial shows that it prevents strokes or heart attacks.
• Cardiovascular events and cancer: no clinically meaningful benefit was seen in the large prevention trials.
• Sepsis: a possible increase in death or organ dysfunction is clinically very significant and is why caution is warranted.
• Macular degeneration: the reduction in progression is meaningful for people at high risk, but it relates to a specific formulation under medical guidance.

For most healthy adults who eat fruits and vegetables, the extra benefit of high-dose supplements is likely to be small, while for people with low intake the benefit of correcting a shortfall is real.

Conflicts of Interest and Funding

Who pays for a trial can influence design, reporting and interpretation, so funding deserves attention.

Many of the landmark prevention trials, including the Physicians' Health Study II and the AREDS study, were funded mainly by US government agencies. As is common, some trials received donated study supplements from manufacturers, which is normally disclosed in the paper, along with whether the sponsor had any role in design or analysis. Large sepsis trials such as LOVIT were publicly funded, while some smaller early studies had links to the clinicians who proposed the therapy.

Supplement research also carries a particular risk: enthusiasm. Authors who have long advocated a therapy may interpret ambiguous results favorably, and positive small trials are more likely to be published than negative ones, a pattern known as publication bias. Readers should check the funding and disclosure statements in every paper and give extra weight to independent, preregistered and publicly funded trials.

Consistency Across Trials

Consistency is one of the main factors used to judge evidence. When many independent studies point in the same direction, confidence rises. When they conflict, confidence falls.

• Highly consistent: large prevention trials of cardiovascular events and cancer repeatedly show no benefit at typical supplemental doses.
• Moderately consistent: the effect on cold duration appears across many trials, though the size varies by dose and population.
• Inconsistent: blood pressure results vary, with differences in baseline blood pressure, dose and study length. In sepsis, small positive studies were not reproduced in larger ones.
• Hard to judge: eye health, because the main trial tested a combination.

When small early studies find a benefit that larger, better-designed trials fail to reproduce, the most likely explanation is that the early result was inflated by chance or bias.

Vitamin C Meta-Analyses and Systematic Reviews

Systematic reviews and meta-analyses pool trials to answer questions that individual studies are too small to settle. The most relevant ones are:

• Cochrane review on the common cold: no reduction in incidence in the general population, a modest reduction in duration, and an apparent benefit in people under intense physical stress.
• Meta-analysis on blood pressure: a small average reduction in short trials, with the authors calling for larger, longer studies.
• Cochrane review on cardiovascular prevention: no evidence of effect on cardiovascular disease events.
• Cochrane review on antioxidant supplements and mortality: no convincing reduction in mortality for ascorbic acid.
• Meta-analysis on serum uric acid: a modest reduction in the lab marker, without evidence on gout attacks.

Meta-analyses are only as good as the trials they combine. When the underlying studies are small, short or inconsistent, pooling them can produce a precise-looking number that is still uncertain. Look at the quality assessment and the amount of heterogeneity, not only the headline result.

Evidence Grading

The grades below are our own editorial assessment, informed by the GRADE approach, which rates certainty based on study design, risk of bias, consistency, directness and precision. They are not an official GRADE rating, and other reviewers may reasonably disagree.

• Reduces cold duration modestly: moderate certainty.
• Does not reduce cold incidence in the general population: moderate to high certainty.
• Reduces cold risk under extreme physical stress: low certainty, because of few small trials.
• Lowers blood pressure slightly: low to moderate certainty, owing to short, varied trials.
• Does not reduce cardiovascular events at about 500 mg per day: moderate to high certainty.
• Does not reduce total cancer incidence at about 500 mg per day: moderate certainty.
• IV use in sepsis improves outcomes: low certainty of benefit, with moderate certainty that large trials show no benefit and possible harm.
• Slows macular degeneration (as part of the AREDS combination): moderate certainty for the combination, very low for the vitamin alone.
• Lowers serum uric acid: low to moderate certainty, with unclear clinical meaning.

Limitations of the Evidence

• Baseline status is often unknown. Many trials did not measure blood levels at the start, so we cannot tell who was deficient and who was not.
• Dose and route vary. Oral 500 mg and IV 50 mg per kilogram are completely different exposures, and results do not transfer between them.
• Diet is hard to separate. People who take supplements often differ in diet, exercise and health habits, which complicates observational studies.
• Surrogate outcomes dominate some questions. Lab markers may not reflect real health benefits.
• Short follow-up. Many trials are too short to detect long-term effects or rare harms.
• Limited subgroup data. Few trials focused on older adults, pregnancy, people with low intake or people with chronic disease.
• Measurement interference. Very high doses, especially IV, can distort some laboratory tests, including certain point-of-care glucose meters, which is a safety issue in clinical settings.
• Evidence changes. New trials may alter these conclusions, so this page should be reviewed periodically.

Safety evidence also deserves a mention. At doses above the 2,000 mg upper limit, gastrointestinal upset such as diarrhea is common. An observational study in men linked supplement use with about double the rate of kidney stones, and people with iron overload conditions such as hemochromatosis are generally advised to avoid high doses because the vitamin increases iron absorption. These are reasons to discuss high doses with a clinician first.

Bottom-Line Interpretation

What should you take from all this? Human trials show that ascorbic acid is essential, that low intake should be corrected, and that supplements may slightly shorten colds. They do not show that high-dose supplements prevent heart disease or cancer, and intravenous use in sepsis has not been shown to help and may harm.

Here is a practical way to apply the evidence:

1. Start with food. Citrus fruit, berries, peppers, kiwi, broccoli and other vegetables can meet the recommended 75 to 90 mg per day easily.
2. Treat supplements as a fix for a gap, not a cure-all. If your diet is limited, a modest dose is reasonable. There is little evidence that going far beyond a few hundred milligrams adds benefit.
3. Stay under the upper limit. The adult limit is 2,000 mg per day unless a clinician advises otherwise.
4. Be skeptical of dramatic claims. Compare any claim with the type of study behind it, and look for randomized trials with clinical endpoints.
5. Talk to a professional. If you have kidney stones, iron overload, kidney disease or a serious illness, or take medicines such as chemotherapy, check with your doctor or pharmacist first.

If you are comparing supplements, check the label for the amount per serving, and look for products that disclose their dose and form clearly. For related topics such as how the vitamin works in the body and how it interacts with medicines, explore our other evidence-based guides.

This article is for general education only and is not medical advice. It does not diagnose, treat or prevent any condition. Consult a qualified healthcare professional before starting or changing any supplement.

References

1. Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;(1):CD000980.
2. Juraschek SP, Guallar E, Appel LJ, Miller ER 3rd. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;95(5):1079-1088.
3. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2008;300(18):2123-2133.
4. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2009;301(1):52-62.
5. Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med. 2007;167(15):1610-1618.
6. Al-Khudairy L, Flowers N, Wheelhouse R, et al. Vitamin C supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;(3):CD011114.
7. Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Engl J Med. 1985;312(3):137-141.
8. Ma Y, Chapman J, Levine M, et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18.
9. Fowler AA 3rd, Truwit JD, Hite RD, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322(13):1261-1270.
10. Fujii T, Luethi N, Young PJ, et al. Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the VITAMINS randomized clinical trial. JAMA. 2020;323(5):423-431.
11. Lamontagne F, Masse MH, Menard J, et al. Intravenous vitamin C in adults with sepsis in the intensive care unit. N Engl J Med. 2022;386(25):2387-2398.
12. AREDS Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-1436.
13. Bjelakovic G, Nikolova D, Gluud C, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012;(3):CD007176.
14. Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res. 2011;63(9):1295-1306.
15. Paulsen G, Cumming KT, Holden G, et al. Vitamin C and E supplementation hampers cellular adaptation to endurance training in humans: a double-blind, randomised, controlled trial. J Physiol. 2014;592(8):1887-1901.
16. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a Recommended Dietary Allowance. Proc Natl Acad Sci USA. 1996;93(8):3704-3709.
17. Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academies Press; 2000.
18. National Institutes of Health, Office of Dietary Supplements. Vitamin C: Fact Sheet for Health Professionals.
19. Thomas LD, Elinder CG, Tiselius HG, Wolk A, Akesson A. Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med. 2013;173(5):386-388.
20. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
21. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.